Combination of Genentech’s Actemra, Gilead’s Remdesivir Enters Phase III Trial for Treatment of Severe...
The global randomized, double-blind, placebo-controlled Phase III trial—to be called REMDACTA—will compare the safety and efficacy of Actemra plus remdesivir to placebo plus remdesivir in severe COVID-19 patients receiving standard of care.
The research “revealed epigenetic alterations to the MEC regulatory landscape that enable reactivation of pregnancy-induced programs in response to pregnancy hormones,” the investigators said, which influenced the development of premalignant lesions in response to oncogene overexpression.
While miRNAs can regulate many genes, they have been shown to have a strong impact on cancer development and on processes such as cancer drug resistance.
The app leverages large cancer data repositories to calculate mortality risks associated with immediate compared with delayed treatment and also takes into account age, cancer type, treatment plan, and presence of other comorbidities.
The genome-wide association study compared the DNA samples and clinical data of healthy thin individuals with normal-weight individuals, in the search for genetic variants linked with thinness. The results highlighted genetic variants in the ALK gene that were specific to the thin individuals.
The study defined recovery as being discharged from the hospital or being medically stable enough to be discharged from the hospital. The median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo
The findings could one day lead to advanced screening methods to discern who is at greatest risk of developing disease, and could help reveal new genetic targets for research and drug development.
Researchers at Mount Sinai have developed a unique algorithm that can rapidly detect COVID-19 based on how lung disease looks in computed tomography (CT scans) of the chest, in combination with patient information including symptoms, age, bloodwork, and possible contact with someone infected with the virus.
The research showed that both mouse and human carriers of the APOE4 gene variant had less melanoma progression and metastasis compared with those who had the APOE2 gene variant, as well as a better response to cancer immunotherapy.
Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected.